Cholesterol

Recent Findings on Cholesterol

• Cholesterol-dependent cancer-cell migration: A study in melanoma investigated the relationship between intracellular cholesterol and amoeboid migration in confined environments. The work reported that statins, including fluvastatin, reduced intracellular cholesterol and suppressed melanoma-cell migration. The findings identify cholesterol-dependent activation of the mechanosensitive channel Piezo1 as a potential link between membrane lipid composition and invasive cell behavior 42715085Sep. This work extends the nanotechnology- and cancer-focused literature context toward pharmacological control of the plasma membrane, Piezo1 signaling, and tumor-cell motility.

• Cholesterol oxidation in prostate cancer immunotherapy: A copper-based single-atom nanozyme platform was designed to combine disulfidptosis and pyroptosis for prostate cancer treatment. The system incorporated cholesterol oxidase, which degraded cholesterol and was reported to inhibit tumor-cell invasion. The enzymatic reaction also increased intracellular hydrogen peroxide, thereby intensifying pyroptosis. This study couples cholesterol metabolism to oxidative stress and inflammatory cell-death pathways, including effects associated with interleukin-1β (IL-1β) and other proinflammatory cytokines 42424164Jul.

• Intracellular cholesterol trafficking: Structural and inhibitor-design studies examined Aster-A, Aster-B, and Aster-C, proteins described as crucial for transporting cholesterol from the plasma membrane to the ER. The work focused on selective nonsteroidal inhibitors of Aster-mediated cholesterol trafficking and on the structural basis of their activity. By targeting movement of cholesterol rather than its synthesis or degradation, the study highlights intracellular distribution as a distinct therapeutic-control point 42679036Sep.

• Biosensing and clinical measurement: A chemiluminescence-functionalized magnetic nanoparticle biosensor was developed for sensitive detection of glucose, uric acid, and cholesterol in human serum. The platform therefore combines cholesterol measurement with analytes relevant to metabolic and inflammatory assessment. Its application illustrates the use of nanomaterials for multiplex biochemical sensing rather than for altering cholesterol biology 42393242Jul.

• Cholesterol-free lipid nanoparticles: A hepatocyte-directed lipid nanoparticle formulation was developed for messenger RNA delivery using cholesterol-free particle compositions. The formulation introduced DY635-functionalized lipids to support targeting and traceability after cholesterol was eliminated from the nanoparticle design. This study addresses how removal of a commonly used helper lipid can be combined with targeting moieties in lipid nanoparticles for mRNA-based gene delivery 42309200Jun.

• Cholesterol as a targeting and membrane-modifying moiety: PAMD-Ch17 was described as a polymeric analog of the CXCR4 inhibitor AMD3100, or plerixafor, containing a cholesterol modification. The compound induced mitochondrial dysfunction in T-cell acute lymphoblastic leukemia cells independently of CXCR4. Here, cholesterol functions as a chemical modification of a therapeutic polymer rather than as the primary metabolic target, potentially linking the construct to cellular membrane interactions and mitochondrial membrane potential 41893624Mar.

• Role in mRNA lipid nanoparticle architecture: A component-level study of mRNA lipid nanoparticles examined the roles of helper lipids, including cholesterol, phospholipid, and PEG-lipid, alongside ionizable lipids. The authors noted that the specific functions of these helper components remain less well understood than those of ionizable lipids. The work places cholesterol within the broader design problem of controlling particle structure and mRNA delivery through lipid composition 42503852Jul.

• Cholesterol and obesity-associated metabolic traits: A multi-country analysis in industrialised countries compared blood pressure, cholesterol, and use of antihypertensive and lipid-lowering medicines among people with obesity and people with normal body mass index. The study also assessed whether excess risk associated with body mass index had diminished. This population-level work places cholesterol measurement alongside body weight, hypertension, and lipid-lowering treatment in the evaluation of metabolic health 42385750Jul.

• Relationship among the recent research themes: Collectively, these publications extend three major areas represented in the surrounding literature. Nanotechnology applications use cholesterol either as a biological target, as a substrate for cholesterol oxidase, as a biosensor analyte, or as a structural component of therapeutic particles. Cholesterol-metabolism research emphasizes intracellular trafficking through Aster proteins and population-level associations with obesity-related metabolic traits. mRNA lipid nanoparticle studies increasingly examine the individual contribution of cholesterol and other helper lipids, including approaches that remove cholesterol and replace its functional or targeting roles with engineered lipid components.